Skip to main content
Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
8.79
-0.88 (-9.10%)
At close: Apr 4, 2025, 4:00 PM
9.00
+0.21 (2.39%)
After-hours: Apr 4, 2025, 7:23 PM EDT

Neurogene Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
0.93---
Cost of Revenue
4.510.947.5142.26
Gross Profit
-3.58-0.9-47.51-42.26
Selling, General & Admin
22.6111.199.018.27
Research & Development
56.4143.5--
Operating Expenses
79.0254.699.018.27
Operating Income
-82.61-55.58-56.52-50.53
Interest Expense
-0.01-0.01-0-
Interest & Investment Income
8.472.951.340.02
Other Non Operating Income (Expenses)
-0.99-0.03-0.01-
EBT Excluding Unusual Items
-75.14-52.67-55.19-50.52
Other Unusual Items
-16.36--
Pretax Income
-75.14-36.32-55.19-50.52
Net Income
-75.14-36.32-55.19-50.52
Preferred Dividends & Other Adjustments
--49.97--
Net Income to Common
-75.1413.65-55.19-50.52
Shares Outstanding (Basic)
18004
Shares Outstanding (Diluted)
18504
Shares Change (YoY)
277.22%1080.37%-90.26%-
EPS (Basic)
-4.2827.76-139.88-12.47
EPS (Diluted)
-4.282.93-139.88-12.47
Free Cash Flow
-71.41-51.74-55.05-64.77
Free Cash Flow Per Share
-4.07-11.11-139.54-15.99
Operating Margin
-8930.27%---
Profit Margin
-8123.68%---
Free Cash Flow Margin
-7720.11%---
EBITDA
-79.36-52.29-53.32-49.59
D&A For EBITDA
3.253.33.20.95
EBIT
-82.61-55.58-56.52-50.53
Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q